Off label use of Chloral Hydrate in the Management of Intrusive Movement and Motor Disorders in Children and Young People – NPPG Position Statement
This position statement outlines considerations for off-label use of chloral hydrate to manage distressing symptoms in movement and motor disorder when all other therapies have failed. It also provides recommendations for where it is being used to treat insomnia.
Source:
Neonatal & Paediatric Pharmacists Group
SPS commentary:
This has been produced to provide guidance for off-label use following the MHRA alert in October 2021 restricting the licensed use of chloral hydrate and cloral betaine to a maximum of 2 weeks for treatment of severe insomnia only in patients with a suspected or confirmed neurodevelopmental disorder and when the insomnia affects normal daily life.